Phase 2 liquid suspension and Phase 1 lyophilized, non-frozen, oral capsules containing live microbes were studied in clinical trials; results are an important step in assessing investigational microbiome-based therapies. Download this press release (175 KB). ROSEVILLE, MN, USA – May 17, 2019 — Rebiotix Inc., a Ferring company, will present data highlighting clinical trials of RBX2660 and […]
Press Releases
MICROBIOME HEALTH INDEX™ Platform to be Presented at Gut Microbiota for Health Summit 2019
Rebiotix’s prototype index is under development to measure impact of microbiota-based therapeutics on Clostridium difficile infection patient microbiomes Microbiome samples from the Rebiotix Phase 2 clinical trials will be featured as part of the index development. Download this press release (381 KB). ROSEVILLE, MN – March 20, 2019 — Rebiotix Inc., a Ferring company, will present analyses of clinical […]
Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month
Proclamation heightens public awareness and impact of the devastating infection Download this press release (328 KB). ROSEVILLE, MN – November 01, 2018 — Rebiotix Inc, a late-stage biotechnology focused on harnessing the power of the microbiome to treat debilitating diseases, joined the C. Diff Foundation today to congratulate the State of Minnesota for declaring November “Clostridium difficile Awareness Month.” Rebiotix, […]
Rebiotix MICROBIOME HEALTH INDEX™ Data to be Presented at United European Gastroenterology Annual Conference
Prototype biomarker data for recurrent Clostridium difficile infections to encompass patient microbiome outcomes data from both microbiota-based therapies Download this press release (327 KB). ROSEVILLE, MN – October 22, 2018 — Rebiotix Inc, a clinical-stage biotechnology part of the Ferring Pharmaceuticals Group, announced today that an expanded microbiome analysis using the proprietary MICROBIOME HEALTH INDEX™ will be presented as […]
Baylor, Rebiotix Find Patient Microbiome Signatures That Differentiate Disease
Novel analysis of large patient microbiome data sets has been utilized to reveal distinct differences between unhealthy and restored gut communities Download this press release (246 KB). ROSEVILLE, MN and HOUSTON, TX. – October 03, 2018 — Rebiotix Inc and Baylor College of Medicine and Texas’s Children’s Hospital announce a collaboration that has resulted in a novel analytical approach to assessing patient […]